← Back to Search

Other

LY3305677 for Obesity

Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a BMI ≥27 kg/m²and <30 kg/m² with at least one weight-related comorbidity such as hypertension on blood pressure (BP)-lowering medication, dyslipidemia on lipid-lowering medication, cardiovascular (CV) disease, or obstructive sleep apnea
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 48

Summary

This trial creates a framework to evaluate the safety and efficacy of weight management interventions. Different interventions can be tested independently.

Who is the study for?
This trial is for adults with obesity, defined as having a BMI ≥30 kg/m², or overweight individuals (BMI ≥27 kg/m² and <30 kg/m²) with weight-related health issues like high blood pressure on medication, cholesterol problems on drugs, heart disease, or sleep apnea. Participants should have maintained their body weight within a 5% range in the past 3 months.
What is being tested?
The study is testing the safety and effectiveness of various potential treatments for chronic weight management. One group will receive an investigational drug called LY3305677 while another group will get a placebo. The interventions are part of separate appendices that can start at different times.
What are the potential side effects?
Specific side effects aren't listed here but typically include reactions at the injection site, gastrointestinal symptoms like nausea or diarrhea, headaches, fatigue and potentially allergic reactions to components of the treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 27 and 30, and I have a weight-related health issue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants Allocated to Each ISA

Trial Design

2Treatment groups
Experimental Treatment
Group I: LY3841136 Obesity ISA LAA1Experimental Treatment2 Interventions
Participants will receive LY3841136 or placebo SC. Each ISA will detail the intervention specific analysis.
Group II: LY3305677 Obesity ISA OXA1Experimental Treatment2 Interventions
Participants will receive LY3305677 or placebo subcutaneously (SC). Each ISA will detail the intervention specific analysis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3841136
2022
Completed Phase 1
~150
LY3305677
2017
Completed Phase 1
~180
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,675 Previous Clinical Trials
3,463,593 Total Patients Enrolled
70 Trials studying Obesity
55,257 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
~144 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top